FDA approves Halozyme’s VYVGART Hytrulo for CIDP treatment

Halozyme Therapeutics, Inc. (NASDAQ: HALO) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approval of VYVGART Hytrulo (efgartigimod alfa and ... Read More